Pharmacokinetics of Losartan and Its Metabolite in Han Healthy Volunteers
GUO Tao1， YANG Lu1，2， XIA Dong-ya1， TANG Yun-biao1，YAN Ming1
Author information+
1.Department of Pharmacy， General Hospital of Shenyang Military Region， Shenyang 110016，China； 2. Department of Pharmacy， Shenyang Pharmaceutical University， Shenyang 110016，China
{{custom_zuoZheDiZhi}}
{{custom_authorNodes}}
{{custom_bio.content}}
{{custom_bio.content}}
{{custom_authorNodes}}
Collapse
History+
Received
Revised
Published
2012-01-01
2012-01-01
2012-01-01
Issue Date
2010-08-15
Abstract
OBJECTIVE To investigate the pharmacokinetics of losartan and its major metabolite， E-3174， in Chinese Han healthy volunteers. METHODS Ten healthy volunteers (5 male and 5 female) were given 50 mg losartan potassium tablets. Blood samples were taken at predetermined time. The concentrations of losartan and E-3174 in plasma were determined by HPLC-fluorescence(FLU) method. The pharmacokinetic parameters were calculated by DAS2.0 software and compared by SPSS13.0 software. RESULTS The pharmacokinetic parameters of losartan and E-3174 were as follows: ρmax ( 351±167) and ( 241±60) μg·L-1, tmax (1.35±1.06) and （3.60±1.68）h, t 1/2 (0.82±0.40) and (4.66±1.10) h, AUC0-24 （498±172） and （1 853±194）μg ·h·L-1, AUC0-∞ (523±184) and (1 960±182) μg ·h·L-1. CONCLUSION The pharmacokinetic characteristics and parameters of losartan and E-3174 had significant inter-individual variability. Individual dose regimens should be used in the clinical treatment.
GUO To;YNG Lu;XI Dong-y;TNG Yun-io;YN Ming.
Pharmacokinetics of Losartan and Its Metabolite in Han Healthy Volunteers[J]. Chinese Pharmaceutical Journal, 2010, 45(16): 1259-1261
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] YUAN Y， LIU X L， GUO X， et al. Bioequivalence of losartan capsules in healthy Chinese male volunteers [J]. Cent South Pharm（中南药学），2007，5(5)：467-470. [2] ALAIN M， YVES C， JURG N， et al.Drug concentration response relationship in normal volunteers after oral administration of losartan， an angiotensin Ⅱ receptor antagonist[J].Clin Pharmacol Ther，1992， 51(5): 513-521. [3] ANDREA S， HILDEGARD S L， EMST M. HPLC Assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats[J]. J Pharm Biomed Anal， 1998， 16(5): 863-873. [4] FARTHING D， SICA D， FAKHRY I， et al . Simple high - performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma ， urine and dialysate [J]. J Chromatogr B， 1997 ， 704(1-2): 374-378. [5] MICHAEL A R， CHRISTINE I F， MAN W L. An improved method for the simultaneous determination of losartan and its major metabolite， EXP3174， in human plasma and urine by high-performance liquid chromatography with fluorescence detection[J]. J Pharm Biomed Anal， 1997， 15(7):1021-1029. [6] TAKASHI I， TERUKAZU T， KEN I H， et al. Method for the simultaneous determination of losartan and its major metabolite， EXP-3174， in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry[J]. J Chromatogr B， 1999，734(2):325-330. [7] YANG P， WANG Y J， LI L， et al. Bioequivalence of losartan capsule and tablet in healthy volunteers [J].Clin J Clin Phamacol（中国临床药理学杂志）， 2006， 22(6):436-439. [8] MICHAEL A， RITTER， CHRISTINE I， et al.An improved method for the simultaneous determination of losartan and its major metabolite， EXP3174， in human plasma and urine by high-performance liquid chromatographic with fluorescence detection[J]. J Pharm Biomed Anal， 1997， 15(7):1021-1029. [9] DON F， DOMENNIC S， ITAF F， et al.Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma， urine and dialydate[J]. J Chromatogr B， 1997， 704(1-2):374-378. [10] WU P B，CHEN Z L，XU W，et al.Study on CYP2C9 gene polymorphism and rational drug use[J]. J China Pharm（中国药房），2007，18(29)：2308-2309. [11] HUANG M，WANG H，PING J，et al. Genetic polymorphism of human CYP3A4 gene in population of Han nationality in China [J]. Chin J Clin Pharmacol Ther(中国临床药理学与治疗学)，2005，11(3)：300-304.
PDF(870 KB)
